PF-06651600 or Placebo

DRUG2 trials

Sponsors

Pfizer

Conditions

HealthyUlcerative Colitis

Phase 1

Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers

CompletedNCT02309827

Start: 2014-12-31End: 2016-04-30Updated: 2016-09-19

Phase 2

Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis

CompletedNCT02958865

PfizerUlcerative Colitis

Start: 2017-02-03End: 2021-05-10Updated: 2022-07-21

Related Papers

Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis.

2024-09-016 citations

Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

The AAPS Journal2024-01-2415 citations

OP09 Oral ritlecitinib and brepocitinib in patients with moderate to severe active Crohn’s Disease: Data from the PIZZICATO umbrella study

Journal of Crohn s and Colitis2024-01-015 citations

Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development

Clinical Pharmacokinetics2023-11-0215 citations

Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics

The AAPS Journal2023-03-2812 citations

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study.

2023-01-0658 citations

Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( <i>S</i> )-2,2-Difluorocyclopropyl)((1 <i>R</i> ,5 <i>S</i> )-3-(2-((1-methyl-1 <i>H</i> -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)

Journal of Medicinal Chemistry2018-08-16165 citations